New Delhi:
On Friday, the Union’s Department of Health revised the dosage of remdesivir, an antiviral medication to be given to patients with moderate-onset coronavirus from the previous six to five days, posting an update clinical management protocols for COVID-19. ‘.
The new drug, given as an injection, should be given at a dose of 200 mg on the first day, then 100 mg per day for four days (five days in total), according to the new treatment protocols.
On June 13, the Ministry of Health authorized the use of remdesivir for limited emergency use in moderate cases as part of “experimental therapy”.
“Under emergency use authorization, remdesivir may be considered for patients at a moderate stage requiring oxygen support,” said the document.
It is not recommended for people with severe kidney failure and a high level of liver enzymes, pregnant and lactating women, and those under the age of 12, he said.
The ministry has also authorized off-label use of tocilizumab, a drug that modifies the immune system or its functioning, and convalescent plasma to treat COVID-19 patients in the moderate stage of the disease as “experimental therapies”.
He also recommended hydroxychloroquine for patients at the onset of the disease and not for critically ill patients.
On June 27, the ministry included, among other therapeutic measures, an inexpensive steroid dexamethasone widely used in treatment protocols for COVID-19 patients in the moderate to severe stages of their disease.
The ministry recommended the use of dexamethasone, which is already used in a wide range of conditions for its anti-inflammatory and immunosuppressive effects, as an alternative to methylprednisolone to manage moderate to severe cases of coronavirus infection.
Indian cases of COVID-19 climbed more than 20,000 in a day for the first time, bringing the country’s total to 625,544 on Friday as the death toll reached 18,213 with 379 new deaths, according to ministry data. Union Health updates at 8 am. .